↓ Skip to main content

Gene Therapy of Solid Cancers

Overview of attention for book
Cover of 'Gene Therapy of Solid Cancers'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy
  3. Altmetric Badge
    Chapter 2 Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model.
  4. Altmetric Badge
    Chapter 3 MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy.
  5. Altmetric Badge
    Chapter 4 Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis
  6. Altmetric Badge
    Chapter 5 Oncoleaking: Use of the Pore-Forming Clostridium perfringens Enterotoxin (CPE) for Suicide Gene Therapy
  7. Altmetric Badge
    Chapter 6 iCaspase 9 Suicide Gene System.
  8. Altmetric Badge
    Chapter 7 p53-Encoding pDNA Purification by Affinity Chromatography for Cancer Therapy
  9. Altmetric Badge
    Chapter 8 A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic.
  10. Altmetric Badge
    Chapter 9 Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
  11. Altmetric Badge
    Chapter 10 RNA Interference for Antimetastatic Therapy
  12. Altmetric Badge
    Chapter 11 STAT3 Decoy ODN Therapy for Cancer.
  13. Altmetric Badge
    Chapter 12 Oncolytic Viral Therapy Using Reovirus
  14. Altmetric Badge
    Chapter 13 Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring
  15. Altmetric Badge
    Chapter 14 Back to the Future: Are Tumor-Targeting Bacteria the Next-Generation Cancer Therapy? - PubMed - NCBI
  16. Altmetric Badge
    Chapter 15 Ethics of Cancer Gene Transfer Clinical Research
  17. Altmetric Badge
    Chapter 16 Planning an Academic Clinical Trial
  18. Altmetric Badge
    Chapter 17 Production of Plasmid DNA as Pharmaceutical
  19. Altmetric Badge
    Chapter 18 Minicircle: Next Generation DNA Vectors for Vaccination.
  20. Altmetric Badge
    Chapter 19 A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
  21. Altmetric Badge
    Chapter 20 Antiangiogenic Metargidin Peptide (AMEP) Gene Therapy in Disseminated Melanoma.
  22. Altmetric Badge
    Chapter 21 Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
Attention for Chapter 17: Production of Plasmid DNA as Pharmaceutical
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Production of Plasmid DNA as Pharmaceutical
Chapter number 17
Book title
Gene Therapy of Solid Cancers
Published in
Methods in molecular biology, January 2015
DOI 10.1007/978-1-4939-2727-2_17
Pubmed ID
Book ISBNs
978-1-4939-2726-5, 978-1-4939-2727-2
Authors

Marco Schmeer, Martin Schleef, Schmeer, Marco, Schleef, Martin

Abstract

Pharmaceutical applications of plasmid DNA require certain quality standards, depending on the intended use of the plasmids. That is, for direct gene transfer into human, GMP Grade is mandatory, however, for GMP production of for example viral vectors (AAV or mRNA etc.), the plasmid DNA used has not to be produced under GMP necessarily.Here we summarize important features of producing plasmid DNA, ensuring the required quality for the intended (pharmaceutical) application.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 20%
Student > Bachelor 3 20%
Professor > Associate Professor 1 7%
Student > Doctoral Student 1 7%
Unknown 7 47%
Readers by discipline Count As %
Agricultural and Biological Sciences 3 20%
Biochemistry, Genetics and Molecular Biology 2 13%
Chemical Engineering 1 7%
Neuroscience 1 7%
Chemistry 1 7%
Other 0 0%
Unknown 7 47%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2023.
All research outputs
#8,061,905
of 24,914,266 outputs
Outputs from Methods in molecular biology
#2,428
of 13,994 outputs
Outputs of similar age
#105,462
of 364,274 outputs
Outputs of similar age from Methods in molecular biology
#166
of 994 outputs
Altmetric has tracked 24,914,266 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 13,994 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,274 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 994 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.